Company: VRCA
Filing Date: 2025-03-11
Form Type: S-3
Source: 0001193125-25-052031
Chunk: 8

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-03-11
Form: S-3
Chunk 8
---
, Suite 400, West Chester, PA 19380 and our telephone number is (484) 453-3300.Our website address is www.verrica.com. The information contained on, or accessible through, our website is not incorporated by reference into this prospectus, and you should not consider any information contained in, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities. Implications of Being a Smaller Reporting Company We are a “smaller reporting company” as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliatesis less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliatesis less than $700 million. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements and reduced disclosure obligations regarding executive compensation. To the extent we take advantage of any reduced disclosure obligations, it may make the comparison of our financial statements with other public companies difficult or impossible.

2

The Securities We May Offer We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, up to a total aggregate offering price of $150,000,000 from time to time under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable:

| • |     | designation or classification; |

| • |     | aggregate principal amount or aggregate offering price; |

| • |     | maturity date, if applicable; |

| • |     | original issue discount, if any; |

| • |     | rates and times of payment of interest or dividends, if any; |

| • |     | redemption, conversion, exercise, exchange or sinking fund terms, if any; |

|